Teleflex (NYSE:TFX) Given New $145.00 Price Target at Mizuho

Teleflex (NYSE:TFX) had its price target hoisted by Mizuho from $140.00 to $145.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the medical technology company’s stock.

TFX has been the subject of several other research reports. Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Raymond James Financial reaffirmed an “outperform” rating and set a $150.00 target price on shares of Teleflex in a research report on Friday, May 8th. Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Finally, Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $160.00 in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $148.00.

Teleflex Price Performance

TFX stock opened at $131.94 on Wednesday. Teleflex has a one year low of $100.18 and a one year high of $139.67. The company’s fifty day moving average price is $130.38 and its 200-day moving average price is $120.30. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The company has a market capitalization of $5.84 billion, a PE ratio of -5.79, a price-to-earnings-growth ratio of 0.97 and a beta of 0.82.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The company had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities analysts anticipate that Teleflex will post 6.7 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, May 25th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s payout ratio is -5.96%.

Institutional Investors Weigh In On Teleflex

Several hedge funds have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise boosted its position in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Teleflex during the fourth quarter worth approximately $37,000. UMB Bank n.a. grew its holdings in shares of Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in Teleflex during the 4th quarter valued at about $45,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Teleflex in the fourth quarter valued at approximately $45,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.